Abstract 174P
Background
Application of computer and artificial intelligence (AI) has made revolutionary progress in medical fields. Computer-assisted diagnosis (CAD) on pathology is successful in diagnosis, classification, staging and predicting prognosis of cancer.
Methods
In this work, we used the technique of convolutional neural networks (CNN) for training of morphological images of gastric cancer, which is a promising application of artificial intelligence technique for medical image analysis, especially for cancer pathology.
Results
We introduced successful works of AI-aided gastric cancer analysis for over 300 cases. AI-assisted pathology technique could help the pathologist in detecting and locating the abnormal area in images and to diagnose and classify benign or malignant tissues. Therefore, AI exactly improves the diagnostic status of gastric cancer, such as in interpretation of medical images and classification between benign and cancerous tissues. The complete workflow of AI diagnosis for gastric cancer is under construction. AI is more useful in releasing pathologists from repeated work, and improving efficiency.
Conclusions
In conclusions, there are still notable technical obstacles before this approach can be used to improve conventional clinical practice. Higher performance needs corrected marking images by experienced pathologist and require ‘training’ algorithms on tremendous data. We stressed the importance of proper algorithms for improving confidence of analytic results that is close to human experts. Additionally, we indicated the gaps in current research and principal resolutions for advancing the field.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors without further recourse to the authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
117P - Short-term and long-term outcomes of hepatectomy combined with intraoperative radiofrequency ablation for multiple colorectal liver metastases: A propensity score matching study
Presenter: Wenbai Huang
Session: Poster display session
Resources:
Abstract
119P - The impacts of dose-time-fractionation schedules on pathological complete response rate (pCR) and local recurrence (LR)
Presenter: Fu Jin
Session: Poster display session
Resources:
Abstract
120P - Platelet to lymphocyte ratio is associated with tumour localization and outcomes in patients with metastatic colorectal cancer
Presenter: Ahmet Bilici
Session: Poster display session
Resources:
Abstract
121P - Meta-analysis of three-dimensional versus two-dimensional laparoscopic surgery for rectal cancer
Presenter: Laiyuan Li
Session: Poster display session
Resources:
Abstract
127P - Outcomes based on albumin‐bilirubin (ALBI) grade in the phase III CELESTIAL trial of cabozantinib versus placebo in patients with advanced hepatocellular carcinoma (HCC)
Presenter: Stephen Chan
Session: Poster display session
Resources:
Abstract
128P - Tislelizumab in combination with chemotherapy for Chinese patients (Pts) with gastric/gastroesophageal junction cancer (GC/GEJC) or esophageal squamous cell carcinoma (ESCC)
Presenter: Yuxian Bai
Session: Poster display session
Resources:
Abstract
129P - Monitoring patient-specific mutation in ctDNA and CTC for tumour response evaluation after neoadjuvant chemotherapy in advanced gastric adenocarcinoma (NCT03425058)
Presenter: Tao Fu
Session: Poster display session
Resources:
Abstract
130P - Development of a liver cancer risk prediction model for the general population in china: A potential tool for screening
Presenter: Xiaoshuang Feng
Session: Poster display session
Resources:
Abstract
131P - Cabozantinib in Asian patients with hepatocellular carcinoma and other solid tumours: Population pharmacokinetics analysis
Presenter: Chih-Hung Hsu
Session: Poster display session
Resources:
Abstract
132P - Liposomal irinotecan (nal-IRI) plus 5-fluorouracil/levoleucovorin (5 FU/LV) vs 5-FU/LV in Japanese patients (pts) with gemcitabine-refractory metastatic pancreatic cancer (mPAC)
Presenter: Tatsuya Ioka
Session: Poster display session
Resources:
Abstract